Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Signal transducers and activators of transcription (STAT) were originally discovered as components of cytokine signal transduction pathways. Persistent activation of one STAT, STAT3, is a common feature of prostate cancer. Activated STAT3 was found in pathology specimens obtained from prostatectomy in the cancerous areas but not in the normal margins. Because the activation of STAT3 is mediated by the action of an upstream Janus kinase (JAK) kinase, usually JAK1 or JAK2, the activation step for STAT3 might itself be a target for therapy in prostate cancer. However, the redundancy of upstream kinases may make this strategy unreliable for therapy. To develop molecular targets for prostate cancer treatment, JAK kinase and STAT3 inhibition of two prostate cancer lines were compared. DU145 and NRP-154 cells were treated with JAK kinase inhibitors, analyzed for onset of apoptosis, and measured by annexin V binding and propidium iodide uptake. Activation of caspases in the cells was determined by measuring cleaved caspase-3 following treatment. For determining the effect on mitochondrial membrane depolarization that accompanies apoptosis, the fluorescent dye JC-1 was used. STAT3 was specifically inhibited by transfecting either a dominant-negative (DN) STAT3 plasmid or antisense STAT3 oligonucleotides into the cells. To look for reduction in STAT3 levels within cells, fixed and permeabilized prostate cancer cells were stained with antibody to STAT3. We found that more than one JAK kinase is involved in STAT3 activation in prostate cancer lines. AG490 (JAK2 specific) induced apoptosis in DU145 but not in NRP-154 prostate cancer lines, whereas piceatannol (JAK1 specific) induced apoptosis in NRP-154 but not in DU145 cells. Next, we demonstrated efficacy of specific STAT3 inhibitors in prostate cancer lines. Both induction of apoptosis and reduction in intracellular STAT3 protein were observed following treatment with antisense STAT3 oligonucleotides, while transfection of a DN-STAT3 plasmid into both prostate cancer cell lines resulted in loss of viability and onset of apoptosis. We conclude that STAT3-specific inhibitors, rather than JAK kinase-specific inhibitors, should be more useful therapeutically in treating androgen-resistant prostate cancer and that STAT3 is an appropriate target in the treatment of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 1×
“demonstrated that inhibition of tumor cell-expressed STAT3 inhibited vascular endothelial growth factor production by the tumor cells (12).”
BackgroundSelf-citationThe role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633
Self-citationImada, K., & Leonard, W. J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00018-3 · Cited by 610 · cited 5×
“AG490 is not a STAT3 inhibitor per se ; it is an inhibitor of JAK2 kinase activity and consequently inhibits the activation of STAT3.”
BackgroundInfluentialGrandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507 · cited 2×
“The STAT3h gene has been described to function as a DN form of the STAT3 gene, inhibiting expression of STAT3 (6, 8, 11, 34).”
BackgroundCaldenhoven, E., van Dijk, T. B., Solari, R., Armstrong, J., Raaijmakers, J. A. M., Lammers, J.-W. J., Koenderman, L., & de Groot, R. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13221 · Cited by 373 · cited 1×
“The STAT3h gene has been described to function as a DN form of the STAT3 gene, inhibiting expression of STAT3 (6, 8, 11, 34).”
BackgroundActivation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation
Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K.-I., Sata, M., Kohara, M., & Yoshimura, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012127 · Cited by 236
Campbell, C. L., Jiang, Z., Savarese, D. M. F., & Savarese, T. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63940-5 · Cited by 151
Cited by
Shin, D.-S., Kim, H.-N., Shin, K. D., Yoon, Y. J., Kim, S.-J., Han, D. C., & Kwon, B.-M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2575 · Cited by 309
Lin, L., Benson, D. M., DeAngelis, S., Bakan, C. E., Li, P., Li, C., & Lin, J. (2012) · International Journal of Cancer · doi:10.1002/ijc.26152 · Cited by 66
JAK-STAT Signaling in Stem Cells
Stine, R. R., & Matunis, E. L. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-6621-1_14 · Cited by 56
Lewis, H. D., Winter, A., Murphy, T. F., Tripathi, S., Pandey, V. N., & Barton, B. E. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0154 · Cited by 25
“published data indicating that benign immortalized prostate cell lines (BPH-1 and NRP-152) were not killed by oligonucleotide 13410 (12).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Barton, B. E., Karras, J. G., Murphy, T. F., Barton, A., & Huang, H. F.-S.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2004-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 11-20
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W4299639679
- Cited by
- 72
- References
- 10
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. https://app.cochat.ai/papers/10.1158/1535-7163.11.3.1
- The paper
- Barton, B. E., Karras, J. G., Murphy, T. F., Barton, A., & Huang, H. F.-S. (2004). Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.11.3.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.